Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00003917

Public ClinicalTrials.gov record NCT00003917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth. PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.

Study identification

NCT ID
NCT00003917
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
4 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 1999 (Type not available)
Primary completion
Nov 2001 (Actual)
Completion
Nov 2001 (Actual)
Last update posted
Jan 9, 2014

1999 – 2001

United States locations

U.S. sites
53
U.S. states
24
U.S. cities
51
Facility City State ZIP Site status
University of Alabama Comprehensive Cancer Center Birmingham Alabama 35294 —
Veterans Affairs Medical Center - Phoenix (Hayden) Phoenix Arizona 85012 —
Comprehensive Blood and Cancer Center Bakersfield California 93309 —
Pacific Coast Hematology/Oncology Medical Group Fountain Valley California 92708 —
Scripps Clinic La Jolla California 92037 —
Veterans Affairs Medical Center - West Los Angeles Los Angeles California 90073 —
Southwest Cancer Care Poway California 92064 —
University of California Davis Cancer Center Sacramento California 95817 —
Kaiser Permanente-Southern California Permanente Medical Group San Diego California 92120 —
Sidney Kimmel Cancer Center San Diego California 92121 —
Oncology Clinic, P.C. Colorado Springs Colorado 80909 —
Shands Cancer Center Gainesville Florida 32610 —
Baptist Regional Cancer Institute - Jacksonville Jacksonville Florida 32207 —
Oncology-Hematology Group of South Florida Miami Florida 33176 —
Baptist Hospital- Pensacola Pensacola Florida 32522 —
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 —
Medical College of Georgia Hospital and Clinics Augusta Georgia 30912-3620 —
Evanston Northwestern Health Care Evanston Illinois 60201 —
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) Hines Illinois 60141 —
Oncology and Hematology Associates, Inc. Indianapolis Indiana 46219 —
Louisiana Oncology Associates Lafayette Louisiana 70506 —
Alton Ochsner Medical Foundation Hospital New Orleans Louisiana 70121 —
Henry Ford Hospital Detroit Michigan 48202 —
St. Joseph Mercy Hospital Pontiac Michigan 48341-2985 —
CCOP - Metro-Minnesota Saint Louis Park Minnesota 55416 —
St. John's Mercy Medical Center St Louis Missouri 63141 —
Cooper Cancer Institute Camden New Jersey 08103 —
St. Barnabas Medical Center Livingston New Jersey 07039 —
Cooper Hospital/University Medical Center Voorhees Township New Jersey 08043 —
Santa Fe Hematology/Oncology Santa Fe New Mexico 87505 —
Rochester General Hospital Rochester New York 14621 —
State University of New York - Upstate Medical University Syracuse New York 13210 —
Salem Research Winston-Salem North Carolina 27103 —
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center Winston-Salem North Carolina 27157-1082 —
Ireland Cancer Center Cleveland Ohio 44106-5065 —
Penn State Geisinger Cancer Center Hershey Pennsylvania 17033 —
Central Pennsylvania Hematology & Medical Oncology Associates, PC Lemoyne Pennsylvania 17043-1440 —
University of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15213 —
Reading Hospital and Medical Center Reading Pennsylvania 19612-6052 —
Brown University Oncology Group Providence Rhode Island 02912 —
Cancer Centers of the Carolinas Greenville South Carolina 29605 —
Spartanburg Regional Healthcare System Spartanburg South Carolina 29303 —
Baptist Regional Cancer Center - Knoxville Knoxville Tennessee 37901 —
Sarah Cannon-Minnie Pearl Cancer Center Nashville Tennessee 37203 —
Texas Cancer Care Fort Worth Texas 76104 —
University of Texas Medical Branch Galveston Texas 77555-0209 —
University of Texas - MD Anderson Cancer Center Houston Texas 77030-4009 —
Joe Arrington Cancer Center Lubbock Texas 79410 —
Scott and White Memorial Hospital Temple Texas 76508 —
Office of Michael E. Lee Norfolk Virginia 23502 —
Hematology & Oncology Associates of Virginia Richmond Virginia 23226 —
Oncology and Hematology Associates of Southwest Virginia, Inc. Roanoke Virginia 24014 —
Waukesha Memorial Hospital Waukesha Wisconsin 53188 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 9, 2014 · Synced Nov 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00003917 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →